# | Title | Journal | Year | Citations |
---|
1 | Targeting TGF-β Signaling in Cancer | Trends in Cancer | 2017 | 697 |
2 | Hypoxia-Inducible Factors: Master Regulators of Cancer Progression | Trends in Cancer | 2016 | 678 |
3 | Turning Cold into Hot: Firing up the Tumor Microenvironment | Trends in Cancer | 2020 | 562 |
4 | RNA-Binding Proteins in Cancer: Old Players and New Actors | Trends in Cancer | 2017 | 528 |
5 | Glutamine Metabolism in Cancer: Understanding the Heterogeneity | Trends in Cancer | 2017 | 472 |
6 | Surviving at a Distance: Organ-Specific Metastasis | Trends in Cancer | 2015 | 419 |
7 | Endoplasmic Reticulum Stress and the Hallmarks of Cancer | Trends in Cancer | 2016 | 406 |
8 | Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance | Trends in Cancer | 2020 | 401 |
9 | Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside | Trends in Cancer | 2018 | 389 |
10 | Glioblastoma: Defining Tumor Niches | Trends in Cancer | 2015 | 326 |
11 | The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity | Trends in Cancer | 2018 | 317 |
12 | Mitochondria, Bioenergetics and Apoptosis in Cancer | Trends in Cancer | 2017 | 299 |
13 | Immunotherapy and Prevention of Pancreatic Cancer | Trends in Cancer | 2018 | 296 |
14 | Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors | Trends in Cancer | 2018 | 286 |
15 | B Lymphocytes and Cancer: A Love–Hate Relationship | Trends in Cancer | 2016 | 284 |
16 | Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment | Trends in Cancer | 2019 | 274 |
17 | Metabolic Regulation of Macrophage Polarization in Cancer | Trends in Cancer | 2019 | 273 |
18 | Radiotherapy: Changing the Game in Immunotherapy | Trends in Cancer | 2016 | 270 |
19 | Hippo Pathway in Cancer: Aberrant Regulation and Therapeutic Opportunities | Trends in Cancer | 2019 | 263 |
20 | Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges | Trends in Cancer | 2017 | 262 |
21 | Senescent Cells in Cancer Therapy: Friends or Foes? | Trends in Cancer | 2020 | 259 |
22 | KRAS Alleles: The Devil Is in the Detail | Trends in Cancer | 2017 | 257 |
23 | Breast Cancer: Multiple Subtypes within a Tumor? | Trends in Cancer | 2017 | 253 |
24 | Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity | Trends in Cancer | 2017 | 252 |
25 | Targeting Transcription Factors in Cancer | Trends in Cancer | 2015 | 247 |
26 | Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment | Trends in Cancer | 2018 | 247 |
27 | Migrating into the Tumor: a Roadmap for T Cells | Trends in Cancer | 2017 | 230 |
28 | Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine | Trends in Cancer | 2016 | 222 |
29 | Long Noncoding RNAs in Cancer: From Function to Translation | Trends in Cancer | 2015 | 218 |
30 | En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition | Trends in Cancer | 2015 | 218 |
31 | Super-Enhancer-Driven Transcriptional Dependencies in Cancer | Trends in Cancer | 2017 | 217 |
32 | Glioblastoma Stem Cells: Driving Resilience through Chaos | Trends in Cancer | 2020 | 217 |
33 | CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer | Trends in Cancer | 2019 | 214 |
34 | YAP/TAZ Signaling and Resistance to Cancer Therapy | Trends in Cancer | 2019 | 213 |
35 | 3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions | Trends in Cancer | 2021 | 209 |
36 | The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies | Trends in Cancer | 2017 | 206 |
37 | The Genetic/Non-genetic Duality of Drug ‘Resistance’ in Cancer | Trends in Cancer | 2018 | 201 |
38 | The Evolving Landscape of Brain Metastasis | Trends in Cancer | 2018 | 194 |
39 | The Immune Biology of Microsatellite-Unstable Cancer | Trends in Cancer | 2016 | 193 |
40 | ALTernative Telomere Maintenance and Cancer | Trends in Cancer | 2015 | 188 |
41 | Polytherapy and Targeted Cancer Drug Resistance | Trends in Cancer | 2019 | 183 |
42 | Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities | Trends in Cancer | 2016 | 177 |
43 | Exosomes as a Multicomponent Biomarker Platform in Cancer | Trends in Cancer | 2020 | 175 |
44 | Modeling Pancreatic Cancer with Organoids | Trends in Cancer | 2016 | 174 |
45 | Clinical Development of BRAF plus MEK Inhibitor Combinations | Trends in Cancer | 2020 | 169 |
46 | Cancer Epigenetics, Tumor Immunity, and Immunotherapy | Trends in Cancer | 2020 | 166 |
47 | Microfluidics: A New Tool for Modeling Cancer–Immune Interactions | Trends in Cancer | 2016 | 163 |
48 | Resisting Resistance: Targeted Therapies in Lung Cancer | Trends in Cancer | 2016 | 162 |
49 | The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View | Trends in Cancer | 2020 | 162 |
50 | Gluconeogenesis in Cancer: Function and Regulation of PEPCK, FBPase, and G6Pase | Trends in Cancer | 2019 | 161 |